Dispersible formulation of levodopa-benserazide in treatment of 204 parkinson disease: a multicenter study / 中国新药与临床杂志
Chinese Journal of New Drugs and Clinical Remedies
;
(12): 97-100, 2001.
Artículo
en Chino
| WPRIM
| ID: wpr-411487
ABSTRACT
AIM:
To study the efficacy and safety of dispersible formulation of levodopa-benserazide on the parkinson disease.METHODS:
The multicenter, open-label, self-controlled trial was conducted at 23 hospitals in 15 cities. Two hundred and four patients with idiopathic parkinson who had received standard levodopa-benserazide previously participated in this study. Dispersible levodopa-benserazide instead of standard levodopa-benserazide for 8 wk as a course. The Webster rating scale and patient diary were applied to assess the efficacy and safety of dispersible levodopa-benserazide. RESULTS: The medication with dispersible levodopa-benserazide increased “on” time by 47 min, decreased “off” time by 11 min, and speeded the onset of “on” time by 37 min. The Webster score was improved by 25 %. Statistical significant difference was calculated (P<0.01). Slight and few adverse reactions were found.CONCLUSION:
Dispersible formulation of levodopa-benserazide is a powerful anti-parkinsonian drug characterized by oral easy use and rapid reach to therapeutic action after ingestion. This drug is particularly used in the parkinsonian patients with morning akinesia, delayed onset of “on” time, afternoon “off” status and dysphagia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Chino
Revista:
Chinese Journal of New Drugs and Clinical Remedies
Año:
2001
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS